UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Cell Competition During Growth and Regeneration

Annual review of genetics, 2015-11, Vol.49 (1), p.697-718

2015

Volltextzugriff (PDF)

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

PloS one, 2019-11, Vol.14 (11), p.e0224267

2019

Volltextzugriff (PDF)

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer

The Journal of experimental medicine, 2018-03, Vol.215 (3), p.895-910

2018

Volltextzugriff (PDF)

MP10-08 PHENOTYPING PATIENTS WITH NEPHROLITHIASIS: CAN WE PREDICT ABNORMAL 24-HOUR URINE PARAMETERS BASED ON INITIAL STONE PRESENTATION?

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task Repetition

Journal of surgical education, 2017-07, Vol.74 (4), p.630-637

2017

Volltextzugriff (PDF)

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Advances in radiation oncology, 2022-09, Vol.7 (5), p.100941-100941, Article 100941

2022

Volltextzugriff (PDF)

Preventive Pharmacologic Therapy for Kidney Stone Disease

JAMA network open, 2024-08, Vol.7 (8), p.e2428927

2024

Volltextzugriff (PDF)

PD34-05 A NOVEL MACHINE-LEARNING ALGORITHM TO PREDICT STONE RECURRENCE WITH 24-HOUR URINE DATA

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Science (American Association for the Advancement of Science), 2017-09, Vol.357 (6356), p.1156-1160

2017

Volltextzugriff (PDF)

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin

Case reports in oncology, 2016-12, Vol.9 (3), p.840-846

2016

Volltextzugriff (PDF)

PD46-08 FOLLOWING THE CROWD: PATTERNS OF CROWDSOURCING ON SOCIAL MEDIA AMONG UROLOGISTS

The Journal of urology, 2017-04, Vol.197 (4), p.e893-e893

2017

Volltextzugriff (PDF)

MP21-13 LOWER SOCIOECONOMIC STATUS IS ASSOCIATED WITH HIGHER URINARY SODIUM: IMPLICATIONS FOR DIETARY STONE GUIDANCE IN UNDERSERVED COMMUNITIES

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

MP45-05 MICRORNA 185-5P IS A NOVEL BIOMARKER ASSOCIATED WITH HIGH-RISK PATHOLOGY AT RADICAL PROSTATECTOMY IN PATIENTS WITH LOW-RISK DISEASE AT DIAGNOSIS

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

Limited relevance of the “very low risk” prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.381-381

2023

Volltextzugriff (PDF)

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Nature (London), 2012-07, Vol.487 (7408), p.500-504

2012

Volltextzugriff (PDF)

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant

The oncologist (Dayton, Ohio), 2021-06, Vol.26 (6), p.467-e924

2021

Volltextzugriff (PDF)

MP47-17 NEDOSIRAN DRAMATICALLY REDUCES SERUM OXALATE IN DIALYSIS-DEPENDENT PRIMARY HYPEROXALURIA 1: A COMPASSIONATE USE CASE REPORT

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Volltextzugriff (PDF)

DOES GENOMIC RISK SCORE AT BIOPSY CORRELATE WITH FOCALITY OF DISEASE AT RADICAL PROSTATECTOMY: IMPLICATIONS FOR FOCAL THERAPY CANDIDATES

Urologic oncology, 2024-03, Vol.42, p.S80-S80

2024

Volltextzugriff (PDF)

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer

Oncogene, 2015-07, Vol.34 (30), p.3968-3976

2015

Volltextzugriff (PDF)

PD13-01 DETERMINING LONG-TERM PROSTATE CANCER OUTCOMES FOR ACTIVE SURVEILLANCE PATIENTS WITHOUT EARLY DISEASE PROGRESSION: WHEN TO SLOW OR STOP SURVEILLANCE

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update

Diagnostic cytopathology, 2019-09, Vol.47 (9), p.912-917

2019

Volltextzugriff (PDF)

MP11-09 PRIOR EXPERIENCE IN ATHLETICS IS SIGNIFICANTLY ASSOCIATED WITH INCREASED ROBOTIC SURGICAL SKILL IN ROBOT-NAIVE MEDICAL STUDENTS

The Journal of urology, 2016-04, Vol.195 (4), p.e114-e115

2016

Volltextzugriff (PDF)

AMPK Activation by Metformin Promotes Survival of Dormant ER + Breast Cancer Cells

Clinical cancer research, 2020-07, Vol.26 (14), p.3707-3719

2020

Volltextzugriff (PDF)

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing

The American journal of pathology, 2019-05, Vol.189 (5), p.956-965

2019

Volltextzugriff (PDF)

Trailblazing Precision Oncology for Rare Tumor Subtypes

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.143-144

2018

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Aktive Filter

ThemaUrology & Nephrology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Englisch
(72)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(35)
Humans
(26)
Female
(19)
Oncology
(16)
Animals
(10)
Breast Cancer
(9)
Breast Neoplasms - Pathology
(8)
Mice
(8)
Breast Neoplasms - Metabolism
(7)
Cancer
(7)
Mutation
(7)
Breast Neoplasms - Drug Therapy
(6)
Cell Line, Tumor
(6)
Prognosis
(6)
Tumors
(6)
Adult
(5)
Antineoplastic Agents - Pharmacology
(5)
Apoptosis - Drug Effects
(5)
Biochemistry & Molecular Biology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cell Competition During Growth and Regeneration

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer

MP10-08 PHENOTYPING PATIENTS WITH NEPHROLITHIASIS: CAN WE PREDICT ABNORMAL 24-HOUR URINE PARAMETERS BASED ON INITIAL STONE PRESENTATION?

Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task Repetition

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Preventive Pharmacologic Therapy for Kidney Stone Disease

PD34-05 A NOVEL MACHINE-LEARNING ALGORITHM TO PREDICT STONE RECURRENCE WITH 24-HOUR URINE DATA

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin

PD46-08 FOLLOWING THE CROWD: PATTERNS OF CROWDSOURCING ON SOCIAL MEDIA AMONG UROLOGISTS

MP21-13 LOWER SOCIOECONOMIC STATUS IS ASSOCIATED WITH HIGHER URINARY SODIUM: IMPLICATIONS FOR DIETARY STONE GUIDANCE IN UNDERSERVED COMMUNITIES

MP45-05 MICRORNA 185-5P IS A NOVEL BIOMARKER ASSOCIATED WITH HIGH-RISK PATHOLOGY AT RADICAL PROSTATECTOMY IN PATIENTS WITH LOW-RISK DISEASE AT DIAGNOSIS

Limited relevance of the “very low risk” prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant

MP47-17 NEDOSIRAN DRAMATICALLY REDUCES SERUM OXALATE IN DIALYSIS-DEPENDENT PRIMARY HYPEROXALURIA 1: A COMPASSIONATE USE CASE REPORT

DOES GENOMIC RISK SCORE AT BIOPSY CORRELATE WITH FOCALITY OF DISEASE AT RADICAL PROSTATECTOMY: IMPLICATIONS FOR FOCAL THERAPY CANDIDATES

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer

PD13-01 DETERMINING LONG-TERM PROSTATE CANCER OUTCOMES FOR ACTIVE SURVEILLANCE PATIENTS WITHOUT EARLY DISEASE PROGRESSION: WHEN TO SLOW OR STOP SURVEILLANCE

Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update

MP11-09 PRIOR EXPERIENCE IN ATHLETICS IS SIGNIFICANTLY ASSOCIATED WITH INCREASED ROBOTIC SURGICAL SKILL IN ROBOT-NAIVE MEDICAL STUDENTS

AMPK Activation by Metformin Promotes Survival of Dormant ER + Breast Cancer Cells

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing

Trailblazing Precision Oncology for Rare Tumor Subtypes

Aktive Filter

Suchergebnisse filtern